ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen & Co. 26th Annual Health Care Conference.CAMBRIDGE, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Cowen & Co. 26th Annual Health Care Conference will be webcast live. The 40-minute presentation is scheduled to begin at 8:50 a.m. on March 9, 2006, and will be given at the Boston Marriott Copley Place Copley Place is an enclosed shopping mall located in the Back Bay section of Boston, Massachusetts. It is part of a complex that includes office buildings, two hotels, and a parking garage. hotel in Boston. The presentation will provide an update on ImmunoGen. The webcast can be accessed through the "Investor Relations Investor relations The process by which the corporation communicates with its investors. " section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until March 16, 2006. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. (TAP) technology uses tumor-targeting antibodies to deliver a potent, cell-killing agent specifically to cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . Three TAP compounds are in clinical testing - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633, which is in development by the sanofi-aventis Group. A fourth TAP compound, trastuzumab-DM1 in development by Genentech, now has an effective IND. Genentech, Centocor (a wholly-owned subsidiary of Johnson & Johnson), Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec , the sanofi-aventis Group, Millennium Pharmaceuticals Millennium Pharmaceuticals NASDAQ: MLNM is a biotechnology company based in the Cambridge, Massachusetts area of the United States of America. Founded in 1993, the company conducts research in various scientific areas, currently focusing on inflammation and oncology. , Inc., Boehringer Ingelheim, and Abgenix have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion